Orthocell Enters Hong Kong Market with First Remplir Surgery and Major Launch Event

Orthocell (ASX: OCC) has marked a significant step in its Asia-Pacific commercial rollout with the successful completion of the first surgical case using Remplir in Hong Kong. The milestone coincides with the product’s official launch at the 45th Annual Congress of the Hong Kong Orthopaedic Association (HKOA), strengthening the company’s foothold in the region’s fast-growing medical device market.

The achievement follows the appointment of MontsMed as Orthocell’s exclusive distributor in Hong Kong. With this partnership in place and regulatory approval secured, Remplir is now available for clinical use and commercial sale in the territory. Hong Kong also serves as a strategic gateway to the Greater Bay Area—a region encompassing nine cities and around 100 million people—with mechanisms in place to import registered devices like Remplir to meet clinical demand.

Orthocell Chief Executive Officer Paul Anderson said the company’s entry into Hong Kong represents measured progress in the broader regional strategy. “The completion of our first Remplir surgical case and successful launch at the Hong Kong Orthopaedic Association Annual Congress represent important progress in our deliberate and considered approach to commercialising Remplir across Asia,” he said. “Hong Kong’s advanced healthcare system and its role as a gateway to the Greater Bay Area present a compelling opportunity for expansion.”

Remplir, Orthocell’s flagship nerve repair device, is now sold in Australia, New Zealand, Singapore, the United States and Hong Kong. Sales in Canada and Thailand are expected to follow shortly. Over the past year, the product has been used in initial surgical procedures across Singapore, the United States and now Hong Kong. These procedures have been supported by an expanding distributor network, with a new Commercial Director recently appointed to oversee operations in Australia and the broader Asia region.

Backed by more than A$50 million in cash and no debt, Orthocell is in a strong financial position to accelerate global adoption of Remplir and drive revenue growth in the 2026 financial year. The company’s expansion into the US market, estimated to be worth US$1.6 billion for nerve repair, is progressing with hospital approvals, onboarding of surgeons and increasing surgical activity.

As Remplir gains traction in key international markets, Orthocell continues to build a foundation for long-term growth, capitalising on demand for advanced regenerative medicine and medical devices that improve patient outcomes.